Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2004

View Archived Issues

Results of first phase III multicenter study of naltrexone depot formulation

Update on fosamprenavir in HIV infection

Preliminary data suggest tipranavir is safe in heavily pretreated HIV-infected patients

Conclusion of phase II study of Liprostin for PVD

Oscient updates status of leading programs

FDA extends Fosrenol review

Eligard six-month product submitted for approval in Canada

Depomed submits Proquin XR NDA

NeuroSearch initiates phase II studies of NS-1209 for refractory status epilepticus

Enrollment completed for Fibrostat phase IIb study

Enrollment underway in PRIMO-CABG-2 study of pexelizumab

Agreement on phase III program for eculizumab for PNH

AGY Therapeutics licenses sigma receptor agonist compound from M's Science

IND active for phase I/II study of TG-100-115

Osel advances Lactin-V into clinical testing

FDA clearance for clinical study of Alferon N in relapsing-remitting MS

Second phase I study planned for CTI-01

Novel antiinflammatory agents trigger apoptosis in cancer cell lines

Sankyo claims immunosuppressive agents

Teva discloses compounds for neurological disorders

YAK3 inhibitors for hematopoietic diseases

Antibacterial agents in early development at GSK

Mixed lineage kinase modulators described in a patent

Agonistic effects described for TAK-559 on different human PPAR subtypes

Clinical improvements found with oxandrolone in HAE